TrialPath
Recruiting

Presynaptic Imaging in Major Depressive Episodes After COVID-19

NCT06086366 · Centre for Addiction and Mental Health
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
Participants will undergo two positron emission tomography (PET) scans, one \[11C\]DTBZ scan (for vesicular monoamine transporter 2 (VMAT2) and one \[18F\]SDM8 scan (for synaptic vesicle glycoprotein 2A (SV2A)), as well as one magnetic resonance imaging (MRI) scan. The main question\[s\] it aims to answer are: 1. The investigators will determine if VMAT2 binding potential (VMAT2 BPND) is reduced in ventral striatum and dorsal putamen in COVID-DNP. 2. The investigators will determine if SV2A total distribution volume (SV2A VT) is reduced in ventral striatum and dorsal putamen in COVID-DNP
Eligibility criteria
Inclusion Criteria: * New onset MDE within 3 months after mild or moderate COVID-19, with MDE verified by the research version SCID for DSM 5. See "Positive COVID-19 diagnosis" listed after inclusion/exclusion criteria for a description of how this is determined. * Age 18 to 75. * Good general physical health with no active medical conditions based on self-report (except migraine or PASC). Exclusion Criteria: * Use of antidepressants in the previous month (6 weeks for fluoxetine). * Use of stimulant medication affecting dopamine release in the previous month * Use of antipsychotics in the previous month * History of neurological disease (except migraine, and PASC) based on self-report * Use of medications or herbal products or natural health products with central nervous system effects in past 2 weeks based on self-report * Presence of cigarette smoking in the past two months, based on self-report * Lifetime diagnosis of severe Substance or Alcohol Use Disorder, or diagnosis of mild to moderate Substance or Alcohol Use Disorder in the past two years, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV) * Use of recreational drugs, including marijuana, in the past two months, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV) * Positive urine drug or cotinine screen at any timepoint during the study * History of psychotic symptoms secondary to schizophrenia, schizophreniform, bipolar disorder, or brief psychotic disorder prior to COVID-19, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV) * Currently pregnant, based on self-report or positive pregnancy test at any timepoint during the study, in females (in our PET Centre females up to 65 years of age are given a urine pregnancy test prior to every PET scan) * Breastfeeding (for females) * Current disorders of coagulation, blood or ongoing use of anticoagulant medication, based on self-report * Claustrophobia, based on self-report * Weight over 400lbs and height over 7ft (requirements for fitting in the scanners and hospital gowns) * Presence of metal implant, object or electrical devices that are contraindicated for MRI, based on self-report * Severe allergic reaction to alcohol
Study design
Enrollment target: 90 participants
Age groups: adult, older_adult
Timeline
Starts: 2023-08-22
Estimated completion: 2028-09-10
Last updated: 2026-02-11
Interventions
Other: [11C]DTBZ PET scanOther: [18F]SDM8 PET scanOther: MRI scan
Primary outcomes
  • Vesicular Monoamine Transporter 2 Binding Potential (VAMT2 BPND) (within 3 to 4 weeks after initiation of screening)
  • Synaptic Vesicle Glycoprotein 2A Total Distribution Volume (SV2A VT) (within 3 to 4 weeks after initiation of screening)
Sponsor
Centre for Addiction and Mental Health · other
Contacts & investigators
ContactKarida Liu · contact · liuyuhan0830@gmail.com · 416-535-8501
ContactJeffrey Meyer · contact · jeffrey.meyer@utoronto.ca · 416-535-8501
InvestigatorJeffrey Meyer, M.D., PhD · principal_investigator, Centre for Addiction and Mental Health
All locations (1)
Centre for Addiction and Mental HealthRecruiting
Toronto, Ontario, Canada
Presynaptic Imaging in Major Depressive Episodes After COVID-19 · TrialPath